Duchenne Muscular Dystrophy Trial Case Study
Source: MRN - Medical Research Network

Administered in two phases, the pediatric study starts with patients aged 7 to 13 and goes up to young adults. During initial treatment the patients go through a phase of double-blind IMP administration before moving into an open label phase. Once that is completed the patients can move into a long-term extension study where patients can remain on treatment for up to 5 years.
VIEW THE CASE STUDY!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.
Subscribe to Clinical Leader
X
Subscribe to Clinical Leader
MRN - Medical Research Network
This website uses cookies to ensure you get the best experience on our website. Learn more